Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
SR 7826 is an inhibitor of LIM kinase 1 (LIMK1; IC50 = 43 nM).1 It is selective for LIMK1 over Rho-associated kinase 1 (ROCK1) and ROCK2 (IC50s = 6,565 and 5,536 nM, respectively) and a panel of 60 kinases at 1 µM but does inhibit serine/threonine kinase 16 (STK16) by greater than 80% at 1 µM. SR 7826 inhibits the phosphorylation of cofilin induced by hepatocyte growth factor (HGF) in A7r5 cells (IC50 = 470 nM). It reduces the migration and invasion of PC3 prostate cancer cells when used at a concentration of 1 µM. SR 7826 (1 µM) inhibits electric field stimulation-, phenylephrine-, methoxamine-, norepinephrine-, or U-46619-induced contractions of prostate strips isolated from patients with prostate cancer.2 In vivo, SR 7826 (10 mg/kg, p.o.) increases apical and basal thin spine density of CA1 pyramidal neurons in the hAPP-J20 mouse model of Alzheimer’s disease.3
WARNING This product is not for human or veterinary use.
1. Bis-
2. Inhibition of human prostate smooth muscle contraction by the LIM kinase inhibitors, SR7826 and LIMKi3. Br. J. Pharmacol. 175(11), 2077-2096 (2018).
3. Pharmacologic inhibition of LIMK1 provides dendritic spine resilience against β-